Design and analysis of non-inferiority mortality trials in oncology by M.!Rothman, N.!Li, G.!Chen and G.Y.H.!Chi, Statistics in Medicine 2003; 22:239-264

被引：2

作者：

Carroll, K ^{[1
]}

Milsted, B ^{[1
]}

Lewis, JA ^{[1
]}

机构：

[1] AstraZeneca, Regulatory Director Global Oncol, Stat Expert Global Oncol, Macclesfield, Cheshire, England

来源：

STATISTICS IN MEDICINE | 2004年 / 23卷 / 17期

关键词：

D O I：

10.1002/sim.1897

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：2771 / 2774

页数：4

共 8 条

[1]

*COMM PROP MED PRO, 2004, EPMPEWP215899DRAFT

[2] Active-control trials:: How would a new agent compare with placebo?: A method illustrated clopidogrel, aspirin, and placebo [J].

Fisher, LD ;

Gent, M ;

Büller, HR .

AMERICAN HEART JOURNAL, 2001, 141 (01) :26-32

[3] Some fundamental issues with non-inferiority testing in active controlled trials [J].

Hung, HMJ ;

Wang, SJ ;

Tsong, YL ;

Lawrence, J ;

O'Neil, RT .

STATISTICS IN MEDICINE, 2003, 22 (02) :213-225

[4]

*ICH TECHN COORD E, 1998, E9 ICH

[5]

*ICH TECHN COORD E, 2000, E10 ICH

[6] Design and analysis of non-inferiority mortality trials in oncology [J].

Rothmann, M ;

Li, N ;

Chen, G ;

Chi, GYH ;

Temple, R ;

Tsou, HH .

STATISTICS IN MEDICINE, 2003, 22 (02) :239-264

[7] The United States Food and Drug Administration and the end of antibiotics [J].

Shlaes, DM ;

Moellering, RC .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :420-422

[8] Utility and pitfalls of some statistical methods in active controlled clinical trials [J].

Wang, SJ ;

Hung, HMJ ;

Tsong, Y .

CONTROLLED CLINICAL TRIALS, 2002, 23 (01) :15-28

← 1 →